145 related articles for article (PubMed ID: 24833530)
1. Evaluating the value of uPAR of serum and tissue on patients with cervical cancer.
Jing J; Zheng S; Han C; Du L; Guo Y; Wang P
J Clin Lab Anal; 2012 Jan; 26(1):16-21. PubMed ID: 24833530
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.
Sasaki T; Nishi H; Nagata C; Nagai T; Nagao T; Terauchi F; Isaka K
Int J Clin Oncol; 2014 Dec; 19(6):1059-64. PubMed ID: 24474395
[TBL] [Abstract][Full Text] [Related]
3. [Expressions and clinical significance of urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) in tongue squamous cell carcinoma].
Wang QX; Wang TX; Sun CF; Zhang J
Shanghai Kou Qiang Yi Xue; 2006 Feb; 15(1):85-7. PubMed ID: 16525618
[TBL] [Abstract][Full Text] [Related]
4. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
5. [Expressions and clinical significance of urokinase-type activator (uPA) and uPA receptor (uPAR) in laryngeal squamous cell carcinoma].
Wang D; Wang T
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Jun; 19(12):529-31. PubMed ID: 16176001
[TBL] [Abstract][Full Text] [Related]
6. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR).
Ye Y; Peng L; Vattai A; Deuster E; Kuhn C; Dannecker C; Mahner S; Jeschke U; von Schönfeldt V; Heidegger HH
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2189-2203. PubMed ID: 32488496
[TBL] [Abstract][Full Text] [Related]
8. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
9. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
[TBL] [Abstract][Full Text] [Related]
10. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
12. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
13. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
[TBL] [Abstract][Full Text] [Related]
14. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
16. Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.
Taubert H; Würl P; Greither T; Kappler M; Bache M; Lautenschläger C; Füssel S; Meye A; Eckert AW; Holzhausen HJ; Magdolen V; Kotzsch M
Br J Cancer; 2010 Feb; 102(4):731-7. PubMed ID: 20051950
[TBL] [Abstract][Full Text] [Related]
17. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
[TBL] [Abstract][Full Text] [Related]
18. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
[TBL] [Abstract][Full Text] [Related]
19. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
20. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]